38806-09-6 Usage
Description
METHYL 1-ACETYLCYCLOPROPYLCARBOXYLATE, also known as 1-Acetylcyclopropanecarboxylic Acid Methyl Ester, is an organic compound that serves as a crucial reagent in the synthesis of various biologically active molecules. It is characterized by its unique cyclopropane ring and ester functional group, which contribute to its reactivity and potential applications in the pharmaceutical and chemical industries.
Uses
Used in Pharmaceutical Industry:
METHYL 1-ACETYLCYCLOPROPYLCARBOXYLATE is used as a reagent for the synthesis of vitamin D carboxylates, which are essential in the development of immunosuppressants, antihyperproliferatives, and vitamin D-active agents. These compounds play a vital role in regulating the immune system, controlling cell proliferation, and maintaining overall health.
Used in Immunosuppressant Applications:
METHYL 1-ACETYLCYCLOPROPYLCARBOXYLATE is used as a key intermediate in the production of immunosuppressants, which are crucial for preventing organ transplant rejection and treating autoimmune diseases. These immunosuppressants help regulate the immune system and promote a healthy balance between immune response and tolerance.
Used in Antihyperproliferative Applications:
METHYL 1-ACETYLCYCLOPROPYLCARBOXYLATE is also used in the synthesis of antihyperproliferatives, which are drugs that inhibit the excessive growth of cells, often associated with conditions like cancer or psoriasis. By controlling cell proliferation, these antihyperproliferatives can help manage and treat various diseases characterized by abnormal cell growth.
Used in Vitamin D-active Agent Applications:
METHYL 1-ACETYLCYCLOPROPYLCARBOXYLATE is utilized in the production of vitamin D-active agents, which are essential for maintaining healthy bone metabolism, immune function, and cellular differentiation. These agents can be used to treat conditions related to vitamin D deficiency and support overall health and well-being.
Check Digit Verification of cas no
The CAS Registry Mumber 38806-09-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,8,8,0 and 6 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 38806-09:
(7*3)+(6*8)+(5*8)+(4*0)+(3*6)+(2*0)+(1*9)=136
136 % 10 = 6
So 38806-09-6 is a valid CAS Registry Number.
InChI:InChI=1/C7H10O3/c1-5(8)7(3-4-7)6(9)10-2/h3-4H2,1-2H3
38806-09-6Relevant articles and documents
Design and Synthesis of 56 Shape-Diverse 3D Fragments
Atobe, Masakazu,Blakemore, David C.,Bond, Paul S.,Chan, Ngai S.,De Fusco, Claudia,Downes, Thomas D.,Firth, James D.,Hubbard, Roderick E.,Jones, S. Paul,Klein, Hanna F.,O'Brien, Peter,Roughley, Stephen D.,Vidler, Lewis R.,Waddelove, Laura,Whatton, Maria Ann,Wheldon, Mary C.,Woolford, Alison J.-A.,Wrigley, Gail L.
supporting information, (2020/07/13)
Fragment-based drug discovery is now widely adopted for lead generation in the pharmaceutical industry. However, fragment screening collections are often predominantly populated with flat, 2D molecules. Herein, we describe a workflow for the design and synthesis of 56 3D disubstituted pyrrolidine and piperidine fragments that occupy under-represented areas of fragment space (as demonstrated by a principal moments of inertia (PMI) analysis). A key, and unique, underpinning design feature of this fragment collection is that assessment of fragment shape and conformational diversity (by considering conformations up to 1.5 kcal mol?1 above the energy of the global minimum energy conformer) is carried out prior to synthesis and is also used to select targets for synthesis. The 3D fragments were designed to contain suitable synthetic handles for future fragment elaboration. Finally, by comparing our 3D fragments with six commercial libraries, it is clear that our collection has high three-dimensionality and shape diversity.
CYANOPYRROLIDINES AS USP30 INHIBITORS AND FIBROSIS TREATMENT
-
Page/Page column 35, (2019/10/01)
The present invention relates to novel treatments of fibrotic diseases, including, inter alia, fibrosis of the lung, liver and kidney, and to substituted-cyanopyrrolidines of formula (I) having activity as inhibitors of ubiquitin specific peptidase 30 (US
NOVEL COMPOUNDS
-
Page/Page column 59, (2016/04/20)
The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.
